Glutamine is an amino acid. Cells are dependent on glutamine in many different ways. Cancer cells in particular are highly dependent on glutamine. Without glutamine, cells would stop growing and eventually die.
Cancer cells’ addiction to glutamine has long tempted cancer biologists as a potential Achilles’ heel for treating the disease. Perhaps by cutting off the supply of this amino acid, one could starve cancer cells to death. Inconveniently, normal cells need glutamine too. Therefore, drugs that affect glutamine levels in the entire body are too toxic to use as cancer therapy.
Now researchers in Johns Hopkins found a compound which blocks glutamine metabolism and can slow tumor growth. Moreover, the compound, a “prodrug” version of the glutamine antagonist DON, selectively targeted tumor cells because they are the “hungriest” for glutamine.
Research showed spectacular results in mice. We all know of course, that most drugs that work in mice don't work in humans, so we should wait for trials in humans to see if such a compound may form the basis of an new effective cancer treatment.